# Ribociclib Natalee study breast cancer results

> Live situation record from CLSTR: https://clstr.news/situations/ribociclib-natalee-study-breast-cancer-results
> Updated: 2026-10-23T13:47:00.000Z. Sources: 8. Developments: 2.

Long-term data from the Phase III Natalee study indicates that ribociclib (Kisqali), when combined with hormone therapy, reduces the risk of death by approximately 19% to 20% in patients with early-stage, HR-positive, HER2-negative breast cancer.

Presented at the 2026 European Society for Medical Oncology (ESMO) Congress, the findings show that survival benefits increased over the six-year observation period. Specifically, the absolute difference in overall survival rose from 1.2% at five years to 2.1% at six years. The study also noted improvements in invasive disease-free survival, which increased from 4.1% at five years to 5.3% at six years.

The research involved approximately 5,100 patients across 20 countries, focusing on high-risk patients in stages II and III. Experts noted that these results reinforce the long-term value of the combination therapy for this patient population.

## Timeline

### 2026-10-23: Ribociclib reduces early breast cancer death risk by 20% in 6-year study

The Phase III Natalee study shows that combining ribociclib with endocrine therapy reduces the 6-year death risk by 20% for high-risk, early-stage HR+/HER2- breast cancer patients.

6 sources. https://clstr.news/cluster/ribociclib-reduces-early-breast-cancer-death-risk-by-20

### 2026-10-23: Novartis Kisqali reduces early breast cancer mortality by 19%

Novartis's Kisqali, combined with hormone therapy, reduced the risk of death by 19% in patients with specific early-stage breast cancers, according to long-term Phase III Natalee study data.

2 sources. https://clstr.news/cluster/novartis-kisqali-reduces-early-breast-cancer-mortality-by-19

---
Cite as: Ribociclib Natalee study breast cancer results. CLSTR, https://clstr.news/situations/ribociclib-natalee-study-breast-cancer-results